Ecomike, i couldn't agree more on NDTP. The risk/reward of a new pharmaceutical company with a solid technology, a fabulous joint venture with a highly respected medical research center, no toxic debt on the books, and run by men with previous business successes on their resume, is enticing to me.
When their filings drop look out, this baby beast will be live.
News 
Market Data 
Discover 
AI
